Novartis AG (NVS) annual results, year to 31 December 2019: revenue USD 47,498 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2019 it reported revenue from the sale of goods of USD 47,498 million, up 5.9% on the year before. Its profit attributable to shareholders was USD 11,732 million, down 7.0%, and diluted earnings per share USD 5.06.
The year to 31 December 2019, against the year before
| Year to | Dec 2018 † | Dec 2019 |
|---|---|---|
| Revenue from the sale of goods | 44,833 | 47,498 |
| Cost of sales | 14,510 | 14,425 |
| Gross profit | 31,589 | 34,252 |
| Research and development | 8,489 | 9,402 |
| Selling, general and administrative | 13,717 | 14,369 |
| Operating profit | 8,403 | 9,086 |
| Profit before tax | 14,095 | 8,940 |
| Income tax | 1,295 | 1,793 |
| Profit for the year | 12,614 | 11,737 |
| Profit attributable to shareholders | 12,611 | 11,732 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2018 † | Dec 2019 |
|---|---|---|
| Cash from operations | 14,272 | 13,625 |
| Purchase of property, plant and equipment | 1,254 | 1,379 |
| Free cash flow | 13,018 | 12,246 |
| Dividends paid | 6,966 | 6,645 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2018 † | Dec 2019 |
|---|---|---|
| Total assets | 145,563 | 118,370 |
| Equity attributable to shareholders | 78,614 | 55,474 |
| Cash and cash equivalents | 13,271 | 11,112 |
| Borrowings, as filed | 25,660 | 22,355 |
| Lease liabilities | n/a | 1,949 |
| Inventories | 6,956 | 5,982 |
| Goodwill | 35,294 | 26,524 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2018 † | Dec 2019 |
|---|---|---|
| Return on year-end equity | 16.0% | 21.1% |
| Effective tax rate | 9.2% | 20.1% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019, this page
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
Source
20-F for the year to 31 December 2019, filed 2 February 2022, accession 0001370368-22-000010: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.